Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seladelpar PK in Hepatic Impairment
NCT03369002Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of seladelpar in primary biliary cholangitis (PBC) (4 arms), sponsored by Gilead Sciences. Primary endpoints: Maximum plasma concentration at 5 days, Time to reach maximum concentration at 5 days and 4 more. Started Nov 2017; status: completed.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT03369002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03369002.